Graft-induced dyskinesia L-DOPA-induced dyskinesia Parkinson's disease Dopamine D 1 receptor Dopamine D 2 receptor Eticlopride SCH23390 Buspirone Cell transplantation Graft-induced dyskinesia (GID) is a serious complication induced by dopamine (DA) cell transplantation in parkinsonian patients. We have recently shown that DA D 2 receptor blockade produces striking blockade of dyskinesia induced by amphetamine in grafted 6-OHDA-lesioned rats, a model of GID. This study was designed to investigate whether blockade of DA D 1 receptors could produce similar outcome, and to see whether the effect of these treatments in grafted rats was specific for dyskinesia induced by amphetamine, or could also influence L-DOPA-induced dyskinesia (LID). L-DOPA-primed rats received transplants of fetal DA neurons into the DA-denervated striatum. Beginning at 20 weeks after transplantation rats were subjected to pharmacological treatments with either L-DOPA (6mg/kg) or amphetamine (1.5mg/kg) alone, or in combination with the D 1 receptor antagonist SCH23390, the D 2 receptor antagonist eticlopride, and the 5-HT 1A agonist/D 2 receptor antagonist buspirone. Grafted rats developed severe GID, while LID was reduced. Both eticlopride and SCH23390 produced near-complete suppression of GID already at very low doses (0.015 and 0.1 mg/kg, respectively). Buspirone induced similar suppression at a dose as low as 0.3 mg/kg, which is far lower than the dose known to affect LID in non-grafted dyskinetic rats. In agreement with our previous results, the effect of buspirone was independent from 5-HT 1A receptor activation, as it was not counteracted by the selective 5-HT 1A antagonist WAY100635, but likely due to D 2 receptor blockade. Most interestingly, the same doses of eticlopride, SCH23390 and buspirone were found to suppress LID in grafted but not in control dyskinetic rats. Taken together, these data demonstrate that the DA cell grafts strikingly exacerbate the effect of DA D 1 and D 2 receptor blockade against both GID and LID, and suggest that the anti-GID effect of buspirone seen in patients may also be due to blockade of DA D 2 receptors.
Introduction
Administration of L-DOPA remains the most effective treatment for Parkinson's disease (PD). However, the appearance of dyskinesia during the progression of the disease has prompted researchers to investigate alternative approaches to treat this debilitating condition. A number of pre-clinical studies demonstrated that transplantation of ventral mesencephalic (VM) cells into the host striatum generates fully mature dopamine (DA) neurons and provides significant restoration of motor functions in animal models (Bjorklund, 1992; Redmond et al., 2008; Winkler et al., 2000) . Based on these promising experimental results, clinical investigations have been performed in advanced PD patients using tissue from aborted foetuses (Freed et al., 1992; Lindvall et al., 1992 Lindvall et al., , 1994 . While open-label trials have provided promising, albeit highly variable, results, double-blind studies have been largely disappointing (Freed et al., 2001; Olanow et al., 2003) . Nevertheless, some of the transplanted patients have greatly benefited from cell grafting, such that they could reduce, or even suspend, L-DOPA treatment, providing proof-of-concept that this approach can yield significant and long-lasting amelioration of motor function. Moreover, recent post-mortem and positron emission tomography (PET) studies have shown that a significant number of grafted DA cells survived in the host caudate/putamen up to sixteen years after transplantation (Li et al., 2010; Mendez et al., 2008; Politis et al., 2010 Politis et al., , 2011 . Most probably, the lack of standardization in the surgical procedures, tissue preparation and patient selection, as well as the presence or absence of post-surgery immunosuppression have contributed to the variability of the results and the negative outcome of the double-blind trials (Barker et al., 2013) . In fact, a new clinical study has recently been funded by the EU FP7 program. The goal of this project is to optimize the procedure for DA cell transplantation using embryonic tissue, with Neurobiology of Disease 62 (2014) 233-240 
